^
Association details:
| Biomarker: | BRCA1 promoter methylation |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinical Activity of Pembrolizumab in a Patient With Metastatic Triple-Negative Breast Cancer Without Tumor Programmed Death-Ligand 1 Expression: A Case Report and Correlative Biomarker Analysis
Published date:
08/07/2017
Excerpt:
A 48-year-old African American woman was diagnosed with left cT3N3 TNBC...Complete radiologic response in the cervical adenopathy was noted after four cycles of pembrolizumab...The primary breast tumor demonstrated BRCA1 PM.
DOI:
10.1200/PO.17.00032
Trial ID:
